A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity

作者：Tseng Feng Jen; Liu Yen Ku; Chung Yo Shong; Lin Yu Ling; Chen Chia Hung; Wang Wan Yi; Chen Yu Cheng; Tsai Nu Man; Cheng Tian Lu; Pan Ru Yu; Hu Tsung Ming; Lee Ru Ping; Liao Kuang Wen^*

来源：Cytotechnology, 2011, 63(3): 285-293.

DOI：10.1007/s10616-011-9340-2

• Vascular endothelial growth factor
• Receptor binding domain of VEGF-A
• Immunoglobulin
• Fusion protein
• Human umbilical vein endothelial cells

Vascular endothelial growth factor (VEGF) promotes the growth of solid tumor mainly via VEGF receptor-1 and receptor-2, which are expressed preferentially in proliferating endothelial cells. Therefore, a strategy for simultaneous blockage of both VEGF receptors may have a useful therapeutic effect in tumor growth. In this study, we utilized a fusion protein which is composed of receptor binding domain of VEGF-A (RBDV) and the constant region fragment (Fc) of a human immunoglobulin G1 (IgG1), to interfere with the growth of human umbilical vein endothelial cells (HUVECs) via VEGF receptors. The results showed that RBDV-IgG1 Fc was able to bind with both VEGF receptor-1 and receptor-2. In addition, RBDV-IgG1 Fc could decrease VEGF-induced proliferation and tube formation among HUVECs. Moreover, the cytotoxic test showed RBDV-IgG1 Fc could also enhance the cytotoxic activity of human natural killing cells. The data are suggesting that the fusion protein, RBDV-IgG1 Fc, may have potential as an angiogenesis antagonist for future tumor therapy.

• 出版日期2011-5
• 单位河北医科大学